Antibe Therapeutics (ATBPD) Stock Price, News & Analysis

Company Overview

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 29,710 shs
• Market Capitalization: $1.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATBPD Stock Analysis - Frequently Asked Questions

How do I buy shares of Antibe Therapeutics?

Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ATBPD
• CIK: N/A
• Web: www.antibethera.com
• Phone: 416 922 3460
• Fax: N/A
• Employees: 47
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,540,000.00
• Net Margins: -273.96%
• Pretax Margin: N/A
• Return on Equity: -150.49%
• Return on Assets: -98.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.97
• Quick Ratio: 5.42

Sales & Book Value

• Annual Sales: $7.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 387,000,000
• Free Float: N/A
• Market Cap: $1.21 billion
• Optionable: Not Optionable
• Beta: 0.57